Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962033 · ClinicalTrials.gov registry record · NA
PRIDE III Prison Interventions and HIV Prevention Collaboration
A NA study of HIV and Opioid Use, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT06962033: Recruiting NA study of HIV and Opioid Use, sponsored by Yale University.
NCT06962033 is a NA study of HIV and Opioid Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 300 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (32% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06962033, a NA study of HIV and Opioid Use, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).
Primary Outcome
Number of patients receiving opioid agonist therapy (OAT) per OAT site.
Conditions Studied
Interventions
- BEHAVIORAL Opioid Agonist Therapy
Study Locations (5)
Other
- Alternative Georgia - Tbilisi
- AIDS Foundation East-West (AFEW) - Bishkek
- NGO AFI - Chisinau
- Institute for International Health and Education (IIHE) - Dushanbe
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT06962033 shows while recruiting
NCT06962033 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Opioid Agonist Therapy is the first listed.
NCT06962033 lists 5 locations in 2 states (Other, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06962033 about?
NCT06962033 is a clinical study titled "PRIDE III Prison Interventions and HIV Prevention Collaboration". The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utiliz...
What is the current status of trial NCT06962033?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-11-05. Estimated completion is 2028-12.
What conditions does trial NCT06962033 study?
This clinical trial studies the following conditions: HIV, Opioid Use.
What interventions are being tested in trial NCT06962033?
The interventions under investigation include: Opioid Agonist Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06962033?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06962033 being conducted?
This trial has 5 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06962033's enrollment target sits among peer trials
300 71st of 303 higher than 231 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI